Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review

Diociaiuti, Andrea; Carnevale, Claudia; Torres, Eulàlia Baselga; Léauté‐Labrèze, Christine; Neri, Iria; Rotunno, Roberta; Figà-Talamanca, Lorenzo; Hachem, May El

doi:10.2340/00015555-3608

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All CNS lesions responded to treatment and five patients had a complete or almost complete resolution of the cutaneous IHs, thus demonstrating that propranolol can pass the blood-brain barrier. This study suggest that oral propranolol should be considered the first-line approach for intra-CNS IHs to avoid possible complications (Diociaiuti et al, 2020).…”

Section: Infantile Hemangiomas With Involvement Of Central Nervous Sy...mentioning

confidence: 81%

Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

et al. 2022

View full text Add to dashboard Cite

Among benign vascular tumors of infancy, hemangiomas are the commonest, affecting approximately 5–10% of one-year-old children. They are derived from a benign proliferation of vascular endothelial cells (VECs) in the mesoderm and may arise anywhere on the body around 1–2 weeks after birth. Infantile hemangiomas (IHs) are characterized by an early proliferative phase in the first year followed by a spontaneous progressive regression within the following 5 years or longer. IH prevalence is estimated to be 5%–10% in one-year-old children and commonly affects female, Caucasian and low-birth weight infants. Although most of them spontaneously regress, approximately 10% requires treatment to prevent complications due to the site of occurrence such as bleeding, ulceration, cosmetically disfigurement, functional impairment, or life-threatening complications. For over 30 years, steroids have represented the first-line treatment for IHs, but recently topical or systemic β-blockers are increasingly being used and recognized as effective and safe. A search for “Cutaneous infantile hemangioma” [All Fields] AND “Treatment” [All Fields] was performed by using PubMed and EMBASE databases. Treatment of IHs with labeled drugs, such as oral propranolol, but also with off-label drugs, such as topical β-blockers, including topical timolol and carteolol, steroids, itraconazole or sirolimus, with a focus on formulations types and adverse events were described in our review. We also discussed the benefits of pulsed dye laser and the treatment of IHs with involvement of central nervous system, namely the PHACE and LUMBAR syndrome.

show abstract

Section: Infantile Hemangiomas With Involvement Of Central Nervous Sy...mentioning

confidence: 81%

Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Propranolol is a nonselective beta-blocker that acts on both β-1 and β-2 adrenergic receptors. Oral propranolol actually represents the first-line approach for the pharmacological treatment of IHs, which suppress lesion proliferation [ 29 – 32 ]. Multiple cutaneous and infantile hepatic hemangiomas respond significantly to propranolol monotherapy in the neonatal period [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients

Xie,

Huang,

Dong

et al. 2024

BMC Pediatr

View full text Add to dashboard Cite

Objectives To explore the clinical characteristics, postnatal treatment and prognosis of giant fetal hepatic hemangioma (GFHH). Method Retrospective analysis was performed on children with giant fetal hepatic hemangioma (maximum tumor diameter > 40 mm) diagnosed by prenatal ultrasound and MRI from December 2016 to December 2020. These patients were observed and treated at the Children’s Hospital of Fudan University after birth. The clinical data were collected to analyze the clinical characteristics, treatment, and prognosis of GFHH using independent sample t tests or Fisher’s exact tests. Results Twenty-nine patients who were detected by routine ultrasound in the second and third trimester of pregnancy with giant fetal hepatic hemangiomas were included. The first prenatal ultrasound diagnosis of gestational age was 34.0 ± 4.3 weeks, ranging from 22 to 39 weeks. Of the patients, 28 had focal GFHHs and 1 had multifocal GFHHs. Surgery was performed, and the diagnosis was confirmed histopathologically in two patients. There were 8 cases with echocardiography-based evidence of pulmonary hypertension, 11 cases had a cardiothoracic ratio > 0.6, and 4 cases had hepatic arteriovenous fistula (AVF). The median follow-up time was 37 months (range: 14–70 months). During the follow-up, 12 patients received medical treatment with propranolol as the first-line therapy. The treatment group had a higher ratio of cardiothoracic ratio > 0.6 (P = 0.022) and lower albumin levels (P = 0.018). Four (14.8%) lesions showed postnatal growth before involuting. Complete response was observed in 13 (13/29) patients, and partial response was observed in 16 (16/29) patients. Conclusions Fetal giant hepatic hemangioma is mainly localized, and its clinical outcome conforms to RICH (rapidly involuting) and PICH (partially involuting), but some fetal giant hepatic hemangiomas will continue to grow after birth and then gradually decrease. For uncomplicated giant fetal hepatic hemangioma, postnatal follow-up is the main concern, while those with complications require aggressive medical treatment. Propranolol may have no effect on the volume change of GFHH.

show abstract

“…Specifically, “fusion” refers to research on genetic fusion or embryological fusion, focusing on the genetic aspects of investigation [ 86 , 87 ]. Additionally, “epilepsy” pertains to investigations concerning central nervous system infantile hemangiomas, with a specific focus on segmental cutaneous infantile hemangiomas, predominantly occurring on the head, neck, upper trunk, lumbar, or sacral region [ 88 ]. These topics exhibit significant development characterized by high density but relatively low centrality.…”

Section: Discussionmentioning

confidence: 99%

Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022

Lin,

Cai,

Shan

et al. 2023

Heliyon

View full text Add to dashboard Cite

Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review

Cited by 5 publications

References 17 publications

Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients

Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022

Contact Info

Product

Resources

About